Share this article on:

Mitomycin C application in resistant caustic esophageal stricture

El-Asmar, Khaleda; Amir, Mohamedb; Abdelkader, Heshama; El-Safoury, Heshama; Hamza, Alaaa

Annals of Pediatric Surgery: April 2011 - Volume 7 - Issue 2 - p 49–54
doi: 10.1097/01.XPS.0000397456.82290.15
Original Articles

Background/purpose: Caustic esophageal strictures still represent a catastrophic problem in children of our country. Management protocol is usually started by regular esophageal dilatation in which multiple sessions may be needed until the resolution of dysphagia; however, in many cases endoscopic dilatation fails and therefore esophageal replacement is eventually required. Our aim is to assess the role of mitomycin C application in the management of caustic esophageal stricture refractory to regular endoscopic dilatation.

Patients and methods: Patients with resistant caustic esophageal stricture were subjected to topical mitomycin C application on stricture site after endoscopic dilatation. Patients were followed up clinically using validated dysphagia score to assess the improvement of dysphagia, radiologically by contrast esophagogram and endoscopically to confirm resolution of the stricture. Results were analyzed and compared with results of a control group managed at the institution by a regular dilatation protocol.

Results: During the period January 2008 to June 2010, 12 patients with resistant caustic esophageal stricture were followed at our unit of whom six had a short esophageal stricture (<3 cm) and six had a long stricture (>3 cm). Topical mitomycin C application resulted in clinical and radiological resolution of dysphagia and strictures in 83% and 66% respectively, compared with 44 (eight out of 18 patients with short stricture) and 25% (two out of eight patients with long stricture) in the control group.

Conclusion: Mitomycin C application can markedly improve the outcome of patients with caustic esophageal stricture, reducing the number of required sessions for endoscopic dilatation. However, double-blinded randomized controlled trial is needed to prove its effectiveness.

aDepartments of Pediatric Surgery

bOtolaryngology, Ain Shams University, Cairo, Egypt

Correspondence to Khaled El-Asmar, MD, Department of Pediatric Surgery, Ain Shams University, Cairo, Egypt Tel: +2 0101222624; e-mail:

Received December 10, 2010

Accepted January 15, 2011

Back to Top | Article Outline


Although the incidence of caustic esophageal strictures has declined in developed countries because of improvement in product packaging and health education, many children in developing countries continue to sustain caustic esophageal injuries from accidental ingestion of alkaline or acidic products, resulting in coagulative or liquifactive necrosis of varied length and depth of the esophagus [1,2].

These esophageal injuries eventually lead to stricture formation in approximately 6 weeks. These strictures require repeated esophageal dilatations, or in severe cases, esophageal replacement. Although a number of agents have been tried experimentally to prevent stricture formation, few have gained clinical application [3].

Mitomycin C (MMC) is an antineoplastic agent that inhibits fibroblast proliferation and reduces collagen cross-linking, which has been proven to be effective in reducing scar formation in animal experiments [2]. In rats, MMC proved to be effective in preventing strictures following experimental caustic esophageal injury, in a dose-dependent manner [3].

MMC has been used successfully with no complications as an adjuvant treatment in several ophthalmological procedures and in laryngotracheal stenosis [4]. Topical application of MMC after dilatation is a new technique that has been recently used for management of esophageal stricture in children, and a few case reports were published; however, no planned studies have been reported yet [2,4–8].

The purpose of this study was to evaluate the effect of MMC topical application after dilatation of caustic esophageal stricture resistant on regular endoscopic dilatation.

Back to Top | Article Outline

Patients and methods

Children presented to the pediatric surgery department, Ain Shams University, with resistant caustic esophageal strictures (who failed to improve after at least 6 months of regular endoscopic esophageal dilatation) were included in this study. Patients with previous esophageal surgery and patients known to have hypersensitivity or contraindication for MMC were excluded from the study.

A detailed history was taken, including time and type of corrosive ingestion, duration and number of previous sessions of endoscopic dilatation, and the degree of dysphagia before and after the previous dilatation period. Degree of dysphagia was evaluated according to a validated dysphagia scoring system [9] (Table 1), and a new barium swallow study was conducted before application of MMC.

Informed consent was taken from the parents after an explanation of the endoscopic technique and the possible associated complications including iatrogenic perforation and failure.

MMC solution (Mitomycin C Kyowa, Biochem Pharmaceutical Industries Ltd, India) was prepared by diluting 10 mg of its commercial powder form in 25 ml of distilled water to reach a concentration of 0.4 mg/ml, to be applied on the stricture site for 5 min estimated using a stopwatch.

Back to Top | Article Outline


Our technique starts by esophageal dilatation using flexible endoscopy and a wire-guided Savary Gilliard dilator under the fluoroscopy. The size of the child's thumb was considered as a rough measure of esophageal lumen and for the appropriate size of the dilator used. After the dilatation, we accurately assessed the stricture site and length by visualizing it endoscopically. Then, application of MMC was followed using a rigid esophagoscope with a piece of cotton soaked in diluted MMC solution that was delivered to the stricture site by a grasper. The soaked cotton piece was kept applied on the esophageal wall at stricture site for 5 minutes. Postendoscopy chest radiograph was a must for exclusion of iatrogenic esophageal perforation.

Back to Top | Article Outline


Patients were followed monthly by the dysphagia score (DS), by the barium swallow study 3 and 6 months after MMC application, and endoscopically 1-month after the session of MMC application for assessment of integrity and continuity of esophageal mucosa over the stricture site.

Our primary endpoint was the number of dilatations required to make the child free of dysphagia.

The results were compared with a control group of patients with caustic esophageal stricture, managed at the same institute in the previous 2 years, who were on a regular dilatation protocol.

Back to Top | Article Outline


From the period January 2008 to June 2010, 12 patients were followed at our unit with resistant caustic esophageal stricture of whom seven were boys and five were girls. Their age at presentation was ranging from 1.75 to 4.5 years (mean: 2.8 years), and all injuries were caused by alkali corrosive ingestion, except one, which was caused by ingestion of an acidic product. Six of them had a short esophageal stricture (<3 cm in length) and the other six had a long stricture (>3 cm in length). These patients underwent multiple sessions of regular endoscopic dilatation with no improvement of their dysphagia; they underwent a mean number of 9.3 dilatation sessions (ranging from 6 to 18 times) within a mean period of 9.5 months (ranging from 6 to 24 months).

All 12 patients were subjected to topical MMC application after dilatation, once for the short strictures and in multiple sessions for the long ones. Patients were followed for a period ranging from 6 to 28 months (mean: 13.6 months).

In the control regular dilatation group, we had 26 patients of which 17 were boys and nine were girls, with age ranging from 1.5 to 5 years (mean: 2.9 years). All had alkali-induced strictures. Eighteen of them had a short stricture, whereas the other eight had a long one.

Patients with short stricture and who had MMC application needed an average of 2.3 dilatation sessions (three patients needed one session, two patients needed two sessions, and the sixth nonresponding patient needed seven sessions till date) to obtain five out of six patients who were completely free of dysphagia, reaching DS=0 (Figs 1 and 2), whereas the sixth patient had only partial improvement with DS=1. In contrast, in the regular dilatation group, we needed an average of 8.3 dilatation sessions (ranging from five to 12 sessions) to obtain only eight out of 18 patients who were completely free of dysphagia (Fig. 3).

Patients with long stricture and who had MMC application needed an average of 5.5 dilatation sessions (ranging from four to 11 sessions) to obtain four out of six patients who were completely free of dysphagia, reaching DS=0 (Figs 4 and 5), whereas the fifth patient had only partial improvement (from DS=2 to DS=1) and the sixth one had not improved at all (DS=2). In contrast, in the regular dilatation group, we needed an average of 11.5 dilatation sessions (ranging from nine to 15 sessions) to obtain only two out of eight patients who were completely free of dysphagia, with no improvement in the rest of the cases (Fig. 6).

It is to be noted that long strictures needed multiple sessions of MMC application; in our patients, we applied it two to five times (mean: 3.8 times) for stricture length ranging from 4 to 7 cm (mean: 5.3 cm).

It is worthy to be mentioned that follow-up endoscopy after MMC application showed healthy esophageal mucosa over the stricture site. No intraoperative or postoperative complications were encountered in both groups of patients (Table 2).

Back to Top | Article Outline


The ideal management of caustic esophageal stricture still represents a great challenge for pediatric surgeons. Serial endoscopic dilatations and esophageal replacement have been used with varying levels of success [1,10]. Esophageal salvage is preferable when possible, but repeated sessions of dilatation may be required because of occurrence of restenosis. The cause of recurrent stricture is unknown, but intense fibrogenesis during healing and after the traumatic dilatation procedure may be the cause, making repeated dilatations necessary, but with an increased risk of complications and perforation [11,12].

In our institution, failure of dilatation of long, multiple, and persistent strictures was an indication of esophageal replacement. The drawbacks of repeated dilatation include psychological problems, withdrawal from school, hospital fears, and familial problems [1,13]. Trials to decrease the number of dilatations, to avoid surgery, and to revert strictures included the use of steroid injection in localized strictures, which increased the intervals between dilatation but did not decrease the need for replacement [1], stents with its high incidence of failure and morbidity [5], and many other inapplicable experimental studies [3,14,15]. Sporadic trials using MMC application on localized strictures have shown better outcome with less number of dilatations [2,5,7,8]. A pilot study conducted at our institute showed marked improvement of the dysphagia with a decrease in the number of dilatations and in the number of replacements.

MMC has an antiproliferative effect on fibroblasts. By bonding to DNA, it inhibits DNA-dependent RNA synthesis and reduces fibroblastic proliferation and collagen bonding [16]. The healthy mucosa that was observed endoscopically after the application of MMC suggested that MMC, by reducing the fibrogenesis process in submucosa, gives the mucosa enough time to creep and to cover the stricture site, which prevents restenosis again; however, biopsy for histopathological examination is required to prove this effect.

No data exist that indicate the most effective concentration, duration, or frequency of application of MMC. We used a solution of 0.4 mg/ml MMC and applied it to the stricture site for 5 min. Other investigators reported usage of 1 mg/ml concentration to be applied for 2 min on a small number of patients with no related complications [5,16]. However, double-blinded randomized trial is needed to justify which concentration and duration is more effective and safer.

In this study, we had six patients with a short esophageal stricture, this group had an excellent response to MMC application with a success rate of 83%. The responding five patients needed only one or two sessions of dilatation and now they are able to eat solid food freely with medium-term follow-up of 6–28 months till date. This represents a much better outcome than that achieved by the other groups of regular dilatation with a lower success rate of 44%, in addition to the need for more numbers of dilatations. Our results were consistent with the other published case reports where they stated the marked response of resistant esophageal stricture, either caustic or anastomotic site strictures, to MMC application [2,5,7,8]. Kumar and Bhatnagar [7] reported a 90% success rate of MMC application on 10 patients with esophageal stricture, of which six of them had postanastomotic stricture and the other four were fresh caustic stricture cases; these patients needed a mean number of 3.4 dilatations.

In the literature, there is no reported trial of MMC application or any other local chemical substance on long caustic esophageal stricture, and no available accurate data about the success rate of regular dilatation on long esophageal stricture, but it is reported that most of them eventually end by esophageal replacement [1]. In our study, the six patients with long esophageal stricture who were subjected to multiple sessions of MMC application obtained a success rate of 66.6% compared with only 25% in the regular dilatation group. The stricture length of 5–6 cm in four patients showed good response to MMC multiple (two–five times) application sessions; these patients can now eat everything with no need for more sessions of dilatation or surgical intervention for 6–23 months of follow-up till date.

Although the success rate of MMC application in long stricture is less than being achieved in short ones with the need for multiple applications, it is worthy to be tried before the decision of esophageal replacement is taken in these patients because, to date, there is no better substitute for the native esophagus; the ideal graft does not exist [1].

Back to Top | Article Outline


MMC topical application can markedly improve the outcome of patients with caustic esophageal stricture, reducing the number of required sessions for endoscopic dilatation. It should be considered as an adjunct new modality and a potential alternative to repeated dilatations, stent placement, or surgery for the management of resistant caustic esophageal strictures, either short or long.

However, prospective double-blinded randomized controlled trial with long-term assessment of outcomes is required to prove the efficacy of MMC in these patients.

Back to Top | Article Outline


The authors thank Dr Mohammed Abdel-Latif, Lecturer of Pediatric Surgery, Ain Shams University, for his assistance during conducting this research.

Back to Top | Article Outline


1. Hamza AF, Abdelhay S, Sherif H, Hasan T, Soliman H, Kabesh A, et al. Caustic esophageal strictures in children: 30 years' experience. J Pediatr Surg. 2003;38:828–833
2. Olutoye OO, Shulman RJ, Cotton RT. Mitomycin C in the management of pediatric caustic esophageal strictures: a case report. J Pediatr Surg. 2006;41:e1–e3
3. Turkyilmaz Z, Sonmez K, Demirtola A, Karabulut R, Poyraz A, Gulen S, et al. Mitomycin C prevents strictures in caustic esophageal burns in rats. J Surg Res. 2005;123:182–187
4. Rahbar R, Jones DT, Nuss RC, Roberson DW, Kenna MA, McGill TJ, et al. The role of mitomycin in the prevention and treatment of scar formation in the pediatric aerodigestive tract: friend or foe? Arch Otolaryngol Head Neck Surg. 2002;128:401–406
5. Uhlen S, Fayoux P, Vachin F, Guimber D, Gottrand F, Turck D, et al. Mitomycin C: an alternative conservative treatment for refractory esophageal stricture in children? Endoscopy. 2006;38:404–407
6. Heran MKS, Baird R, Blair GK, Skarsgard ED. Topical mitomycin-C for recalcitrant esophageal strictures: a novel endoscopic/fluoroscopic technique for safe endoluminal delivery. J Pediatr Surg. 2008;43:815–818
7. Kumar A, Bhatnagar V. Topical application of mitomycin-C in corrosive esophageal strictures. J Indian Assoc Pediatr Surg. 2005;10:25–27
8. Fröhlich T, Greess H, Köhler H. Topical mitomycin C treatment of a benign oesophageal stricture following caustic ingestion in a four-year-old boy. Z Gastroenterol. 2007;45:255–258
9. Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med. 1993;329:1302–1307
10. Erdogan E, Eroglu E, Tekant G, Yeker Y, Emir H, Sarimurat N, et al. Management of esophagogastric corrosive injuries in children. Eur J Pediatr Surg. 2003;13:289–293
11. Yeming W, Somme S, Chenren S, Huiming J, Ming Z, Liu DC. Balloon catheter dilatation in children with congenital and acquired esophageal anomalies. J Pediatr Surg. 2002;37:398–402
12. Lan LC, Wong KK, Lin SC, Sprigg A, Clarke S, Johnson PR, et al. Endoscopic balloon dilatation of esophageal strictures in infants and children: 17 years' experience and a literature review. J Pediatr Surg. 2003;38:1712–1715
13. Han Y, Cheng QS, Li XF, Wang XP. Surgical management of esophageal strictures after caustic burns: a 30 years of experience. World J Gastroenterol. 2004;10:2846–2849
14. Gunel E, Caglayan F, Caglayan O, Canbilen A, Tosun M. Effect of antioxidant therapy on collagen synthesis in corrosive esophageal burns. Pediatr Surg Int. 2002;18:24–27
15. Apaydin BB, Paksoy M, Artis T, Sahin DA, Aki H, Uslu E. Influence of pentoxifylline and interferon-alpha on prevention of stricture due to corrosive esophagitis. An experimental study in the rat. Eur Surg Res. 2001;33:225–231
16. Daher P, Riachy E, Georges B, Georges D, Adib M. Topical application of mitomycin C in the treatment of esophageal and tracheobronchial stricture: a report of 2 cases. J Pediatr Surg. 2007;42:e9–e11

caustic esophageal stricture; esophageal dilatation; mitomycin C

© 2011 Annals of Pediatric Surgery